ClinicalTrials.gg
Not yet recruitingNCT07896291PBAAR-NSUpdated Oct 26, 2026

Prevelance of Broncial Asthma and Allergic Rhinitis in Children With Nephrotic Syndrim

An observational study in Bronchial Asthma, Allergic Rhinitis and Allergic Disease in Nephrotic Children at Sohag University, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Sohag University · Observational

Updated Oct 26, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
20
Ages
2 Years to 18 Years
Sex
All
01

Study summary

This is a study at sohag university hospital aim to determine the precelance of Bronchial Asthma and Allergic Rhinitis among children with Nephrotic Syndrom

Read the detailed description

This study aims to determine the prevalence of bronchial asthma and allergic rhinitis among children with nephrotic syndrome attending Sohag University Hospital. The study will assess the occurrence of these allergic conditions in children aged 2-18 years and explore their clinical characteristics and possible associations with nephrotic syndrome. The findings may help improve the recognition and management of allergic diseases in children with nephrotic syndrome.

02

Conditions studied

  • Bronchial Asthma
  • Allergic Rhinitis
  • Allergic Disease in Nephrotic Children at Sohag University
  • Prevelance of Bronchial Asthma and Allergic Rhinitis Among Children With Nephrotic Syndrom at Sohag University Hospital

Keywords

  • Nephrotic Syndrom
  • Allergic Rhinitis and Bronchial Asthma
03

In context

Asthma

4,012 studies on the registry are indexed under Asthma; 514 are open to participants now.

This study's planned enrollment of 20 is below the median of 150 across 993 observational studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

Sohag University is the lead sponsor of 1,220 studies on the registry; 629 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Children diagnosed with nephrotic syndron Aged 2 to 18 year attending at sohag university hospital

Eligibility criteria

Children diagnosed with nephrotic syndron Aged 2 to 18 year

-

Exclusion Criteria:

  • children below 2 years
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Children aged from 2 to 18 years old ,diagnosed with Nephrotic Syndrom

    No intervention

06

What researchers measure

Primary outcomes

  1. Prevelance of Bronchial Asthma and Allergic Rhinitis among Children with Nephrotic Syndrom at Sohag University Hospital

    Prevelance of Bronchial Asthma and Allergic Rhinitis among Children with Nephrotic Syndrom at Sohag University Hospital

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Indivisuals participants data will not be shared due to privacy protection policies at sohag university hospital

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2026
First posted
Oct 26, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07896291
Lead sponsor
Sohag University
Responsible party
Samah Khaled Elsaman (Pediatric resident at sohag university hospital, Sohag University) — Principal investigator
First posted
Oct 26, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Mar 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Samah Khaled Elsaman
Contact
Samah.Khaled@med.sohag.edu.eg
01011262937

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion